Shelf life (days): 1460.0
Formulation: A solid
Formal Name: (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-6-13C-6,6-d2-3-carbonitrile, monohydrochloride
Purity: ≥99% deuterated forms (d1-d2)
Formula Markup: C17[13C]H23D2N3O2 / HCl
Formula Weight: 354.9
CAS Number: 2699827-95-5
Notes: Saxagliptin-13C-d2 is intended for use as an internal standard for the quantification of saxagliptin (Item No. 23697) by GC- or LC-MS. Saxagliptin is a potent inhibitor of dipeptidyl peptidase 4 (DPP-4; Ki = 0.6 nM).{40437} It inhibits DPP-4 ex vivo (ED50 = 0.12 μmol/kg) in plasma from normal fasted rats. Saxagliptin (0.3-3 mg/kg) reduces plasma glucose levels in Zuckerfa/fa diabetic rats in a dose-dependent manner. Oral administration at doses ranging from 1-10 μmol/kg increases plasma insulin levels and improves glucose clearance in ob/ob mice, a transgenic model of obesity. Saxagliptin induces systolic and diastolic dysfunction, reduces contractile force, and exacerbates ischemia-reperfusion injury-induced cardiac dysfunction in isolated guinea pig hearts.{40438} Formulations containing saxagliptin have been used for the treatment of type 2 diabetes.
English
Deutsch
